Biologic dose escalation in inflammatory bowel disease in the United States.

ABSTRACT:

Background

Treatment for inflammatory bowel disease (IBD), composed of Crohn disease (CD) and ulcerative colitis (UC), frequently employs biologics to help control inflammation, reduce symptom burden, and limit disease progression. Because of both the lifelong, progressive nature of disease and potential for loss of therapy response over time, therapy changes are common. Biologic dose escalation is one method to adjust therapy regimens following loss of response.

Objective

To assess the occurrence of dose escalation in CD and UC and its influence on health care costs.

Methods

Adults with a diagnosis of CD or UC newly initiating therapy with a biologic (adalimumab, infliximab, ustekinumab, vedolizumab, or tofacitinib [UC only]) from January 1, 2017, to June 30, 2022, w

SUBMITTER: Chapman C 

PROVIDER: S-EPMC12948753 | biostudies-literature | 2026 Mar

REPOSITORIES: biostudies-literature